What is CAM2029?

Why should I participate in a CAM2029 clinical trial?

CAM2029 is a new investigational, long-acting (depot) formulation containing the well-established ingredient octreotide, which is under development for the treatment of acromegaly. CAM2029 is being tested in clinical trials and is not commercially approved.

CAM2029 is supplied in a prefilled syringe with a 22G needle and is ready to use. It is administered under the skin (subcutaneous) by the doctor or by the patient or by their partner, after appropriate training.

CAM2029 has been tested in healthy volunteers and patients in early stage clinical trials.